| Patient | Emily Dickinson |
|---|---|
| Date of birth | 1971-12-10 |
| Identifiers | MRN HR-NI023-SYN; SSN (made up) 000-23-6081 |
| Document date | 2026-09-28 |
| Author | Lucinda Hartwell, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Video visit for the six-month kidney review. [S]
Ms. Dickinson is seen by video from her home; the mobile phlebotomy service drew blood and collected a urine sample this morning, and she measured her vital signs with her own devices before the call. She feels well, with no headaches since the spring. Her home blood pressure averages 118/72. She takes losartan 100 mg, dapagliflozin 10 mg, amlodipine 5 mg, atorvastatin 20 mg, and vitamin D3 daily and has taken no NSAIDs. She has had no lightheadedness, ankle swelling, urinary symptoms, or muscle aches. She would like her second hepatitis B dose and her influenza vaccine at her preventive visit next month, so that she makes one trip. [S]
| Element | Detail |
|---|---|
| Visit format | Video visit from home, with home-measured vital signs and a home blood and urine collection |
| Symptoms | No headaches since the spring |
| Home blood pressure | Average 118/72 mmHg |
| Medication tolerance | No lightheadedness, edema, urinary symptoms, or muscle aches |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No ankle swelling or lightheadedness |
| Genitourinary | Negative | No urinary symptoms or genital itching |
| Neurological | Negative | No headaches |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naproxen sodium 220 mg oral tablet, two tablets by mouth as needed for headache (over the counter) | Two tablets as needed, up to twice a day | Oral route | 2025-10-01 to 2026-01-12 | stopped | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 to 2026-02-02 | completed | S |
| Losartan 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-02-02 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day | Two tablets every 6 hours as needed; maximum 6 tablets a day | Oral route | 2026-01-12 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-02-02 | active | S |
| Amlodipine 5 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-02 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-28 | Body height | 163 | cm | S |
| 2026-09-28 | Body weight | 53.4 | kg | S |
| 2026-09-28 | Body mass index (BMI) [Ratio] | 20.1 | kg/m2 | S |
| 2026-09-28 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-09-28 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-09-28 | Heart rate | 68 | /min | S |
| 2026-09-28 | Respiratory rate | 14 | /min | S |
| 2026-09-28 | Body temperature | 36.5 | Cel | S |
| 2026-09-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-28 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-09-28 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-28 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-09-28 | Urea nitrogen [Mass/volume] in Serum or Plasma | 21 | mg/dL | 6-21 mg/dL | Normal | S |
| 2026-09-28 | Creatinine [Mass/volume] in Serum or Plasma | 1.28 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-09-28 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 50 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-09-28 | Glucose [Mass/volume] in Serum or Plasma | 90 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-09-28 | Albumin/Creatinine [Mass Ratio] in Urine | 96 | mg/g | <=30 mg/g | High | S |
| 2026-09-28 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-09-28 | Phosphate [Mass/volume] in Serum or Plasma | 3.6 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 2026-09-28 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 61 | pg/mL | 15-65 pg/mL | Normal | S |
| 2026-09-28 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 36 | ng/mL | 30-100 ng/mL | Normal | S |
Vital signs recorded on 2026-09-28; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General (video) | Well and animated; respiratory rate 14 counted on video |
| Extremities (video) | No pitting seen when she pressed on her shins |
| Mental status (video) | Alert and engaged; euthymic |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic kidney disease stage G3a A2, attributed to hypertension; synthetic modern diagnosis linked to the Bright's disease entered on her death certificate | active | confirmed | N18.31 | S — Synthetic modern diagnosis. Bright's disease as her recorded cause of death is documented (D); what it meant in her case is a retrospective question (R), and no kidney test from her lifetime exists. |
| Hypertension with chronic kidney disease (hypertensive chronic kidney disease, stage 3a); synthetic modern diagnosis linked to the retrospective view that she had severe hypertension | active | confirmed | I12.9 | S — Synthetic modern diagnosis; severe hypertension is a retrospective interpretation (R, possible), and no blood pressure from her lifetime exists. |
| Vitamin D deficiency with a mildly raised PTH in chronic kidney disease | active | confirmed | E55.9 | S — Synthetic laboratory finding at the intake visit. |
| Viral gastroenteritis with volume depletion and a prerenal rise in creatinine while taking losartan and dapagliflozin; resolved | resolved | confirmed | A08.4 | S — Synthetic illness at an unscheduled home visit, chosen to teach sick-day rules in chronic kidney disease; it does not echo any documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | eGFR with metabolic panel | Twice a year at G3a A2 (KDIGO heat map) | Completed today | Potassium 4.6 mmol/L, creatinine 1.28 mg/dL, eGFR 50 |
| Laboratory | Urine albumin-creatinine ratio | Twice a year at G3a A2 (KDIGO heat map) | Completed today | 96 mg/g, down from 240 at intake |
| Laboratory | Calcium, phosphate, and PTH | Every 6 to 12 months at G3a | Completed today | Calcium 9.4 mg/dL, phosphate 3.6 mg/dL, PTH 61 pg/mL |
| Laboratory | 25-hydroxyvitamin D after repletion | At baseline; repeated according to level and treatment | Completed today | 36 ng/mL on vitamin D3 |
| Examination | Standardized home blood pressure on a validated cuff | Every visit | Completed today | 118/74 mmHg today; home average 118/72 |
| Examination | Weight | Every visit | Completed today | 53.4 kg on her home scale |
| Examination | Cardiac auscultation | Every visit | Deferred | Not possible at a video visit; no cardiac symptoms. Done at the June home visit and planned at next month's preventive visit |
| Examination | Fundoscopic examination | Yearly in chronic hypertension | Due | Planned at next month's preventive visit |
| Laboratory | Hemoglobin and KFRE | Yearly in G3 | Up to date | Hemoglobin 12.3 g/dL and KFRE 0.5 and 1.6 percent in January; due again in January |
| Laboratory | Lipid panel | Once at diagnosis (KDIGO); yearly in the CMID hypertension schedule | Not indicated | On atorvastatin for chronic kidney disease; KDIGO advises no routine repeat lipid testing |
| Medication safety | Medication review: NSAID avoidance, SGLT2 inhibitor and statin safety | Every visit | Completed today | No NSAIDs; no genital, urinary, or muscle symptoms |
| Medication safety | Vaccination review | Yearly in chronic kidney disease | Due | HepB-CpG dose 2, influenza, and zoster dose 1 planned at next month's preventive visit, at her request, to avoid an extra trip; dose 2 remains well within the schedule |
| Self-management | Sodium, activity, and home readings | Every visit | Completed today | Low-salt cooking; garden work most afternoons |
Goal progress:
Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026)
Follow-up: Preventive visit at the clinic next month. Yearly kidney tests and review in January. Next scheduled visit 2026-10-19: periodic adult preventive visit. [S]